Presbyopia
Drug research and approvals for presbyopia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 24 studies of presbyopia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 24
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of Functional Superiority of the Morrow eProgressiveNCT07878416 · Not applicable · Morrow Eyewear · starts Sep 24, 2026
- Volumetric Visual Fields at Different Distances in Presbyopic Patients Using Occupational (PC-133 and PC-200) and…NCT07870785 · Not applicable · University of Seville · starts Jun 8, 2026
- Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact LensesNCT07638943 · Not applicable · Gordon Schanzlin New Vision · starts May 20, 2026
- VisDura VisAbility™ Micro Insert System Pre-market Clinical TrialNCT07637500 · Not applicable · VisDura, Inc. · starts Jun 2, 2026
- Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and…NCT07617090 · Not applicable · University of Seville · starts Sep 29, 2025
- Clinical Performance of Verofilcon A Toric Contact LensesNCT07586982 · Not applicable · Southern College of Optometry · starts Apr 1, 2026
- Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and KeratoconusNCT07559188 · Not applicable · Azalea Vision · starts Sep 28, 2026
- Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A…NCT07512089 · Not applicable · Zhongshan Ophthalmic Center, Sun Yat-sen University · starts May 12, 2026
- Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid AberrometryNCT07436247 · Not reported · Prim. Prof. Dr. Oliver Findl, MBA · starts Apr 4, 2024
Phase 3 5
- PilocarpineMuscarinic acetylcholine receptor M3 agonist
- Cilmostim
- CarbamoylcholineMuscarinic acetylcholine receptor M3 agonist
- BrimonidineAdrenergic receptor alpha-2 agonist
- PhentolamineAdrenergic receptor alpha antagonist
Phase 2 4
- OxymetazolineAdrenergic receptor alpha agonist
- Arlipoic acid choline ester
- TropicamideMuscarinic acetylcholine receptor M3 antagonist
- Aceclidine
Phase 1 or earlier 1
- BromfenacCyclooxygenase inhibitor
How its trials ended
296 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 53 whose ending is known, 57% met their primary endpoint, 2% missed it and 42% stopped early.
- Completed, result not reported16957%
- Ongoing4014%
- Status unknown3411%
- Met its primary endpoint3010%
- Stopped: other or unclear114%
- Stopped: enrollment or feasibility52%
- Stopped: sponsor or business decision52%
- Missed its primary endpoint1<1%
- Stopped: lack of efficacy1<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jun 23, 2021 | A randomized, placebo-controlled, double-masked, multi-center, dose-ranging study to evaluate the safety, and efficacy of UNR844 in subjects with presbyopiaUNR844 | Novartis Pharmaceuticals | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA